RedHill Biopharma (RDHL) EV to EBITDA (2013 - 2023)

RedHill Biopharma (RDHL) has reported EV to EBITDA for 11 consecutive years, with 34.19 the latest figure, recorded in Q2 2023.

• On a quarterly basis, EV to EBITDA fell 99.32% year-over-year to 34.19 in Q2 2023; TTM through Jun 2023 was 41.81, a 91.02% increase from a year earlier, with the FY2025 full-year figure at 1.08, up 99.56% from the prior year.
• EV to EBITDA was 34.19 for Q2 2023 at RedHill Biopharma, up from 217.15 in the prior quarter.
• Over five years, EV to EBITDA peaked at 24925.72 in Q3 2020 and troughed at 959.8 in Q4 2021.
• A 5-year average of 10461.42 and a median of 10358.9 in 2021 frame the typical range for EV to EBITDA.
• Across the five-year window, EV to EBITDA soared 129.22% in 2019 and tumbled 106.1% in 2021, its largest moves.
• Over 5 years, EV to EBITDA stood at 18194.04 in 2019, then retreated by 13.49% to 15740.45 in 2020, then tumbled by 106.1% to 959.8 in 2021, then soared by 88.1% to 114.21 in 2022, then surged by 129.94% to 34.19 in 2023.
• The last three EV to EBITDA figures came in at 34.19 (Q2 2023), 217.15 (Q1 2023), and 114.21 (Q4 2022), per Business Quant data.